ClinicalTrials.gg
Sign In
TerminatedNCT04210102CAPUERAUpdated Nov 4, 2026

Community-Acquired Pneumonia Diagnosis Using Lung Ultrasound in Emergency Room Adults

An interventional study of Lung Ultrasound (LUS) and Chest radiography (CR) in Community-acquired Pneumonia, sponsored by Centre Hospitalier Universitaire de Nice. Terminated at 1 site in Monaco. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Centre Hospitalier Universitaire de Nice · Not applicable, Interventional, and Diagnostic

Why this study was terminated
The study was terminated prematurely due to insufficient recruitment.
Updated Nov 4, 2026Now TerminatedStudy completion movedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Community-Acquired Pneumonia (CAP) is a major problem in Emergency Department (ED). Diagnosis relies on combination of clinical symptoms and results of chest radiography (CR). Patients' management (treatment, support) depends on delay and quality of the diagnosis. However, signs and symptoms are highly aspecific and interpretation of CR is subject to frequent discrepancies. Then diagnosis of CAP may be uncertain; therefore, overdiagnosis is frequent and leads to over-use of antimicrobial therapy; missing diagnosis is also deleterious and delays adequate treatment including antibiotics. CT scan completes CR and helps clinician making properly diagnosis of CAP; obtaining CT in a 4-hour time-lapse allows better diagnosis and management as accurate as an independent expert adjudication committee does. However availability of CT as well as radiation interrogates on the benefit that Lung Ultrasounds (LUS) may have in diagnosis strategy of suspected CAP. LUS is a noninvasive easy-to-use device whose practice is widely endorsed worldwide by emergency medicine associations and societies. Additionally, previous studies advocate for the use of LUS for diagnosis of CAP in the ED. Therefore the Promotor developed a study to compare LUS and CR as a primary imaging for diagnosis of CAP at the ED.

02

Conditions studied

  • Community-acquired Pneumonia
03

In context

Community-Acquired Pneumonia

324 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.

This study's enrollment of 47 is below the median of 250 across 195 interventional studies indexed under Community-Acquired Pneumonia.

Browse Community-Acquired Pneumonia studies →

Lead sponsor

Centre Hospitalier Universitaire de Nice is the lead sponsor of 723 studies on the registry; 176 are open to participants now.

Browse Centre Hospitalier Universitaire de Nice studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (18+)
  • Suspected CAP by attending emergency physician
  • And new onset of systemic infection (at least one among sweat, chills, aches and pain, temperature ≥38°C or \<36°C)
  • And symptoms of an acute lower respiratory tract infection (at least one among cough, sputum production, dyspnea, chest pain, altered breathing sounds at auscultation
  • No previous imaging for the current medical problem
  • Inform consent (signed)
  • Affiliation to insurance (France, Monaco)

Exclusion criteria

Exclusion Criteria:

  • Age below 18-year of age
  • Patients in palliative care
  • Pregnant women
  • anticipated barriers to completing follow-up data collection,
  • patients classified three or higher according to the CRB65 score,
  • patients requiring intensive care for any purpose because of specific management of critically ill
  • refusal to participate to the study
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Other
    CR + LUS

    Patient will be performed first the Chest radiography then the Lung ultrasound.

    Diagnostic Test: Lung Ultrasound (LUS) · Diagnostic Test: Chest radiography (CR)

  • Other
    LUS + CR

    Patient will be performed first the Lung ultrasound then the Chest radiography

    Diagnostic Test: Lung Ultrasound (LUS) · Diagnostic Test: Chest radiography (CR)

Interventions

  • Diagnostic testLung Ultrasound (LUS)

    Lung Ultrasound : Ultrasound is a medical imaging technique that relies on the use of ultrasound, inaudible sound waves, which allow to "visualize" lungs.

  • Diagnostic testChest radiography (CR)

    The chest X-ray is a medical imaging examination that provides images of the lungs through the X-ray pulse.

06

What researchers measure

Primary outcomes

  1. The sensitivity of lung ultrasound (LUS) and chest X-ray (CR) to detect community-acquired pneumonia (CAP) will be mesured and compared in patients visiting the emergency department for suspected CAP

    Time frame: Within the day of inclusion

Secondary outcomes

  1. specificity, positive predictive value and negative predictive value : indicators of diagnosis performance, will be measured and compared as a primary imaging for diagnosis of CAP

    Time frame: Within the day of inclusion

  2. Specificity, positive predictive value, negative predictive value will be measured and compared in each sequence of imaging (CR + LUS and LUS + CR) for CAP detection

    Time frame: Within the day of inclusion

  3. medical decisions for diagnosis of CAP after each step LUS then CR or CR then LUS and after low dose CT6scan (CT) will be compared to the medical decisions of the adjudication committee

    Time frame: Up to 6 months

  4. The concordance of interpretation (for CR and CT) between attending radiologist and expert radiologist of the adjudication committee (gold standard) wil be studied.

    Time frame: Up to 6 months

07

Study locations

1 site
  • CHPG
    Monaco, Monaco
08

References and documents

Publications

  • Dorca J, Torres A. Lower respiratory tract infections in the community: towards a more rational approach. Eur Respir J. 1996 Aug;9(8):1588-9. doi: 10.1183/09031936.96.09081588. No abstract available. PubMed 8866576 ↗
  • Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J Suppl. 2002 Jul;36:20s-27s. doi: 10.1183/09031936.02.00702002. PubMed 12168744 ↗
  • Claessens YE, Debray MP, Tubach F, Brun AL, Rammaert B, Hausfater P, Naccache JM, Ray P, Choquet C, Carette MF, Mayaud C, Leport C, Duval X. Early Chest Computed Tomography Scan to Assist Diagnosis and Guide Treatment Decision for Suspected Community-acquired Pneumonia. Am J Respir Crit Care Med. 2015 Oct 15;192(8):974-82. doi: 10.1164/rccm.201501-0017OC. PubMed 26168322 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2020 to primary completion in Jan 2025, 59 months.

Completion moved once since we started tracking on Sep 25, 2026: Jan 2026 → Jan 2025, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2019
First posted
Dec 24, 2019
StartActual
Feb 11, 2020
Primary completionActual
Jan 28, 2025
CompletionActual
Jan 28, 2025was Jan 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated The study was terminated prematurely due to insufficient recruitment.
changed Nov 4, 2026
Study completion
Jan 28, 2026→Jan 28, 2025 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Active, not recruiting→Terminated
    Why stopped The study was terminated prematurely due to insufficient recruitment.
    Study completion Jan 28, 2026→Jan 28, 2025 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04210102
Lead sponsor
Centre Hospitalier Universitaire de Nice
Collaborators
Centre Hospitalier Princesse Grace
Responsible party
Sponsor
First posted
Dec 24, 2019
Start date
Feb 11, 2020
Primary completion
Jan 28, 2025
Completion
Jan 28, 2025
Last update
Nov 4, 2026

Study contacts

CLAESSENS Yann-Erick, MD, PhD
principal investigator · CH Princesse Grâce

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Community-Acquired Pneumonia →

Other studies from this sponsor

Centre Hospitalier Universitaire de Nice →

Start the discussion